Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case

Bradley A Connor; Mara Couto-Rodriguez; Joseph E Barrows; Morgan Gardner; Marina Rogova; Niamh B O'Hara; Dorottya Nagy-Szakal

doi:10.1016/j.ijid.2021.07.029

Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case

Int J Infect Dis. 2021 Sep:110:232-234. doi: 10.1016/j.ijid.2021.07.029. Epub 2021 Jul 13.

Authors

Bradley A Connor¹, Mara Couto-Rodriguez², Joseph E Barrows², Morgan Gardner³, Marina Rogova³, Niamh B O'Hara⁴, Dorottya Nagy-Szakal⁴

Affiliations

¹ Weill Cornell Medicine, New York, NY, USA; The New York Center for Travel and Tropical Medicine, New York, NY, USA; GeoSentinel, New York, NY, USA. Electronic address: bconnor1@gmail.com.
² Biotia, Inc., New York, NY, USA.
³ The New York Center for Travel and Tropical Medicine, New York, NY, USA; GeoSentinel, New York, NY, USA.
⁴ Biotia, Inc., New York, NY, USA; SUNY Downstate Health Sciences University, The Department Cell Biology/College of Medicine, New York, NY, USA.

Abstract

We present two Delta (B.1.617.2) vaccine breakthrough individuals, a father and son living in separate households. The older, 63-year-old patient's symptoms were severe enough to require hospitalization. Despite having a high titer of anti-spike IgG in his serum, his symptoms resolved within 24 hours following monoclonal antibody (bamlanivimab/etesevimab) therapy.

Keywords: B.1.617.2; COVID-19; Delta variant; SARS-CoV-2; bamlanivimab/etesevimab; breakthrough; monoclonal antibody therapy; variant of concern.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / therapeutic use
COVID-19*
Humans
Middle Aged
SARS-CoV-2
Vaccines*

Substances

Antibodies, Monoclonal
Vaccines